A detailed history of Polar Capital Holdings PLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Polar Capital Holdings PLC holds 1,937,930 shares of SUPN stock, worth $70.7 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares
1,937,930
Previous 1,940,510 0.13%
Holding current value
$70.7 Million
Previous $51.9 Million 16.41%
% of portfolio
0.37%
Previous 0.32%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$25.77 - $35.16 $66,486 - $90,712
-2,580 Reduced 0.13%
1,937,930 $60.4 Million
Q1 2024

May 15, 2024

BUY
$27.11 - $35.17 $31,040 - $40,269
1,145 Added 0.06%
1,940,510 $66.2 Million
Q4 2023

Feb 14, 2024

BUY
$22.72 - $29.68 $6.47 Million - $8.46 Million
284,895 Added 17.22%
1,939,365 $56.1 Million
Q3 2023

Nov 14, 2023

BUY
$27.57 - $32.91 $4.14 Million - $4.94 Million
150,000 Added 9.97%
1,654,470 $45.6 Million
Q2 2023

Dec 13, 2023

BUY
$29.91 - $38.73 $3.5 Million - $4.53 Million
117,055 Added 8.44%
1,504,470 $45.2 Million
Q2 2023

Aug 14, 2023

BUY
$29.91 - $38.73 $3.5 Million - $4.53 Million
117,055 Added 8.44%
1,504,470 $45.2 Million
Q1 2023

Dec 13, 2023

SELL
$34.93 - $42.03 $9.33 Million - $11.2 Million
-267,055 Reduced 16.14%
1,387,415 $50.3 Million
Q1 2023

May 15, 2023

BUY
$34.93 - $42.03 $12.9 Million - $15.5 Million
368,295 Added 36.14%
1,387,415 $50.3 Million
Q4 2022

Feb 14, 2023

BUY
$31.09 - $37.88 $7 Million - $8.52 Million
225,000 Added 28.33%
1,019,120 $36.4 Million
Q2 2022

Aug 15, 2022

SELL
$25.33 - $34.25 $2.12 Million - $2.87 Million
-83,825 Reduced 9.55%
794,120 $23 Million
Q1 2022

May 16, 2022

BUY
$28.51 - $32.9 $7.13 Million - $8.23 Million
250,000 Added 39.81%
877,945 $28.4 Million
Q4 2021

Feb 14, 2022

BUY
$26.37 - $34.22 $16.6 Million - $21.5 Million
627,945 New
627,945 $18.3 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.95B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Polar Capital Holdings PLC Portfolio

Follow Polar Capital Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Polar Capital Holdings PLC with notifications on news.